2021
DOI: 10.3389/fsurg.2021.665115
|View full text |Cite
|
Sign up to set email alerts
|

Identification and Validation of a Prognostic 5-Protein Signature for Biochemical Recurrence Following Radical Prostatectomy for Prostate Cancer

Abstract: Background: Biochemical recurrence (BCR) is an indicator of prostate cancer (PCa)-specific recurrence and mortality. However, there is a lack of an effective prediction model that can be used to predict prognosis and to determine the optimal method of treatment for patients with BCR. Hence, the aim of this study was to construct a protein-based nomogram that could predict BCR in PCa.Methods: Protein expression data of PCa patients was obtained from The Cancer Proteome Atlas (TCPA) database. Clinical data on th… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 35 publications
(40 reference statements)
0
1
0
Order By: Relevance
“…Recently, protein-based prognostic risk models have gained more and more attention because the detection of tumor protein biomarkers is economical, reliable, reproducible, and more accessible in clinical practice. It is reported that protein-based prognostic models have been successfully constructed and validated predictive accuracy in patients with breast carcinoma and prostate carcinoma [ 8 , 9 ]. To date, the protein-based prognostic signature has rarely been used to predict the prognosis of GC patients.…”
Section: Introductionmentioning
confidence: 99%
“…Recently, protein-based prognostic risk models have gained more and more attention because the detection of tumor protein biomarkers is economical, reliable, reproducible, and more accessible in clinical practice. It is reported that protein-based prognostic models have been successfully constructed and validated predictive accuracy in patients with breast carcinoma and prostate carcinoma [ 8 , 9 ]. To date, the protein-based prognostic signature has rarely been used to predict the prognosis of GC patients.…”
Section: Introductionmentioning
confidence: 99%